hp 873 has been researched along with mdl 100907 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hopkins, CR | 1 |
| Fan, Y; He, X; Jia, M; Li, J; Li, W; Liu, M; Zhou, Y | 1 |
| Stahl, SM | 1 |
1 review(s) available for hp 873 and mdl 100907
| Article | Year |
|---|---|
ACS chemical neuroscience molecule spotlight on Fanapt.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Device Approval; Dopamine Agonists; Humans; Isoxazoles; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; United States; United States Food and Drug Administration | 2010 |
2 other study(ies) available for hp 873 and mdl 100907
| Article | Year |
|---|---|
Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Topics: Antipsychotic Agents; Chromatography, Liquid; Dopamine D2 Receptor Antagonists; Humans; Isoxazoles; Liquid-Liquid Extraction; Male; Piperidines; Sensitivity and Specificity; Serotonin 5-HT2 Receptor Antagonists; Tandem Mass Spectrometry | 2013 |
Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Humans; Isoxazoles; Piperidines; Serotonin 5-HT2 Receptor Antagonists | 2013 |